Developer docs
API playgroundTry for free, no card

Search company profiles

Neumentum

Full company profile

uuid0002kkc

Namestring
Neumentum
Legal namestring
Neumentum, Inc.
Websiteurl
neumentum.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Neumentum, Inc. is a privately held, clinical-stage specialty pharmaceutical company developing a portfolio of non-opioid analgesic products to address the opioid crisis in pain management. Founded in 2017 and headquartered in Morristown, New Jersey (with a corporate address in Summit, NJ), the company operates with a small team of 1–10 employees and is led by co-founders Scott Shively (CEO) and Joseph Pergolizzi, M.D. (Executive Chairman), supported by CSO Robert B. Raffa, Ph.D. (formerly of Johnson & Johnson) and CMO Ilona Steigerwald, M.D. (formerly of Grünenthal).

The company's pipeline centers on two lead assets: NTM-001, a novel alcohol-free formulation of ketorolac (an NSAID) in a pre-mixed IV bag designed for 24-hour continuous infusion to manage moderately severe acute postoperative pain — potentially the first NSAID approved for continuous infusion in the U.S., with patent protection through 2032; and NTM-006, a non-opioid, non-NSAID, non-gabapentinoid new chemical entity licensed from Johnson & Johnson in 2019, in development as a once-daily oral treatment for chronic neuropathic and nociplastic pain. Supporting pipeline candidates include NTM-002 (an IV patient-controlled analgesia candidate) and additional early-stage non-opioid programs.

Neumentum's business model is pre-commercial and primarily licensing-oriented. It generates limited revenue through upfront payments, milestone payments, and royalties from licensing partnerships — most notably the October 2020 agreement with Nuance Biotech granting exclusive China development and commercialization rights for NTM-001 ($3M upfront, up to $50M in milestones, plus low-double-digit royalties). The planned U.S. go-to-market is enterprise field sales targeting hospital procurement, pharmacy & therapeutics committees, and anesthesia/pain specialists for formulary adoption. The company has been funded through multiple equity rounds totaling approximately $34–36M, including a 2017 Series A and a 2023 exempt securities offering of up to $20M to support Phase 3 execution.

Short descriptiontext

Neumentum is a clinical-stage pharmaceutical company developing a portfolio of novel non-opioid analgesic products, including an IV ketorolac formulation (NTM-001) and an oral analgesic NCE (NTM-006), targeting hospital-based acute and chronic pain markets to address the opioid crisis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMorristown, United States
HQ citystring
Morristown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-opioid analgesics, pain management pharmaceuticals, acute postoperative pain, chronic neuropathic pain, neurology specialty drugs
Industry3 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Non-opioid analgesics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Revenue
TypeLicensing Royalties
Description

Licensing agreements for NTM-001 and NTM-006 generate upfront payments, milestone payments tied to development and regulatory achievements, and royalty payments on net sales.

neumentum.com
2Equity Financing
TypeSubscription Recurring
Description

Exempt securities offerings to raise capital for development operations. $20 million offering with $16.56 million already sold per SEC Form D.

sec.gov
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neumentum develops and commercializes novel non-opioid pain pharmaceutical products. Its lead candidate NTM-001 is an alcohol-free, pre-mixed bag formulation of ketorolac designed for 24-hour continuous IV infusion for moderately severe postoperative acute pain. NTM-006 is a non-opioid, non-NSAID, non-gabapentinoid oral new chemical entity for chronic neuropathic and nociplastic pain. The company has four non-opioid candidates in development targeting hospitals and chronic pain patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Steady plasma levels of ketorolac over 24 hours demonstrated in Phase I study with 67 subjects
+1 more record
Product overview1 text field

Neumentum is a specialty pharmaceutical company developing a portfolio of non-opioid analgesic products for pain management. The company's core pipeline includes NTM-001 (an IV alcohol-free ketorolac formulation in pre-mixed bag for 24-hour continuous infusion targeting acute postoperative pain), NTM-006 (an oral non-opioid, non-NSAID new chemical entity for chronic neuropathic and nociplastic pain), NTM-002 (IV patient-controlled analgesia candidate), and early-stage pipeline candidates. The company aims to address the opioid crisis by providing effective pain relief without the risks of abuse, misuse, diversion, or life-threatening respiratory depression associated with opioids.

Product and service4 records
1NTM-001 (ketorolac pre-mixed bag for continuous infusion)
CategoryAcute pain pharmaceutical
Description

Investigational, alcohol-free, stable formulation of ketorolac (an NSAID) in a pre-mixed bag designed for 24-hour continuous IV infusion in postoperative settings. Developed for management of moderately severe acute pain requiring analgesia at the opioid level, with the goal of reducing or eliminating opioid use after surgery. Target customers are hospitals, surgical centers, and anesthesia/pain management specialists.

2NTM-006 (oral analgesic, formerly JNJ-10450232)
CategoryChronic pain pharmaceutical
Description

Once-daily oral new chemical entity (NCE) that is non-opioid, non-NSAID, and non-gabapentinoid, with a novel mechanism of action. In development for chronic neuropathic and nociplastic pain, addressing patients with limited safe long-term oral options. Licensed-in from Johnson & Johnson Family of Companies.

3NTM-002 (IV patient-controlled analgesia candidate)
CategoryAcute pain pharmaceutical
Description

Early-stage IV patient-controlled analgesia candidate with potential to deliver opioid-strength analgesia, intended to reduce the need for opioids in clinical acute pain settings.

4Early Stage Pipeline
CategoryPain pharmaceutical pipeline
Description

Early-stage non-opioid pharmaceutical pipeline candidates for the treatment of acute and chronic pain, both in the United States and globally, completing a portfolio of four novel non-opioid products.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2021-09-20
Description

Clinical research organization partnership, jointly nominated for Citeline Awards 2021 for Most Successful Early-Phase Research. NEMA Research provides clinical trial services for Neumentum's pain management product development.

2Nuance Biotech Co. Ltd
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-10-21
Description

Licensing agreement granting Nuance exclusive rights to develop and commercialize NTM-001 (ketorolac for IV infusion) in China. Neumentum receives $3 million upfront payment with potential development, regulatory and sales milestone payments up to $50 million plus low-double-digit percentage royalties on net sales. Nuance is a China-based specialty pharmaceutical company focused on pain management, founded in 2014.

neumentum.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-10-10
Description

Global licensing agreement for JNJ-10450232 (now NTM-006) and portfolio of backup compounds. JNJ-10450232 is a novel oral analgesic compound that is neither an opioid nor NSAID, with Phase 2A clinical studies completed. Licensed from Johnson & Johnson Family of Companies.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-10-10
Description

Part of Johnson & Johnson Family of Companies, co-licensor of NTM-006 oral analgesic compound.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty pharmaceutical company developing non-opioid and oncology-supportive care products, including post-operative pain therapies (HTX-011/Zynrelef). Directly comparable as a non-opioid pain-focused specialty pharma with hospital channel commercialization.

TypeDirect peer
Description

Commercial-stage specialty pharma focused on non-opioid pain management with Exparel (bupivacaine liposome injectable suspension). The most established non-opioid post-surgical pain company, comparable for both product category and hospital formulary GTM motion.

TypeDirect peer
Description

Specialty pharma focused on non-opioid pain therapeutics, with FDA-approved OLINVYK (oliceridine), an IV opioid agonist for moderate-to-severe acute pain. Comparable as a small-cap non-opioid pain developer with similar hospital-channel commercialization.

TypeDirect peer
Description

Clinical-stage biopharma developing novel peripherally-acting kappa opioid receptor agonists for chronic pruritus and pain. Comparable as a small specialty pharma targeting non-opioid pain pathways with similar development-stage profile.

TypeDirect peer
Description

Specialty pharma commercializing DSUVIA (sufentanil sublingual) and ZALVISO for acute pain in medically supervised settings. Comparable focus on opioid-sparing or alternative pain therapies with hospital/clinical channel strategy.

TypeDirect peer
Description

Clinical-stage biopharma developing non-opioid treatments for chronic pain (e.g., CNTX-6016, capsaicin-based therapies). Directly comparable as a pure-play non-opioid pain therapeutics developer targeting similar patient populations.

TypeEmerging player
Description

Specialty pharma with ANJESO (meloxicam IV) for moderate-to-severe pain and a non-opioid portfolio. Comparable as a small-cap non-opioid pain developer with hospital-channel commercialization focus.

TypeEmerging player
Description

Clinical-stage biopharma developing CA-008, a non-opioid prodrug of capsaicin for post-surgical pain. Directly comparable as an emerging non-opioid acute pain developer with similar Phase-stage profile.

TypeBroad incumbent
Description

Global pharmaceutical incumbent with established ketorolac generic franchise (Toradol) and broad pain portfolio. Comparable as a competitor and potential strategic acquirer/partner for non-opioid pain assets with deep hospital relationships.

TypeBroad incumbent
Description

Privately-held European specialty pharma with deep focus on pain management (including Qutenza, tapentadol/Palexia). Highly comparable as a chronic and acute pain specialist incumbent and potential strategic acquirer given Neumentum's CMO Ilona Steigerwald previously led late R&D there.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neumentum

Non-opioid analgesicsneumentum.com

Neumentum is a clinical-stage pharmaceutical company developing a portfolio of novel non-opioid analgesic products, including an IV ketorolac formulation (NTM-001) and an oral analgesic NCE (NTM-006), targeting hospital-based acute and chronic pain markets to address the opioid crisis.

What Neumentum does

Neumentum, Inc. is a privately held, clinical-stage specialty pharmaceutical company developing a portfolio of non-opioid analgesic products to address the opioid crisis in pain management. Founded in 2017 and headquartered in Morristown, New Jersey (with a corporate address in Summit, NJ), the company operates with a small team of 1–10 employees and is led by co-founders Scott Shively (CEO) and Joseph Pergolizzi, M.D. (Executive Chairman), supported by CSO Robert B. Raffa, Ph.D. (formerly of Johnson & Johnson) and CMO Ilona Steigerwald, M.D. (formerly of Grünenthal).

The company's pipeline centers on two lead assets: NTM-001, a novel alcohol-free formulation of ketorolac (an NSAID) in a pre-mixed IV bag designed for 24-hour continuous infusion to manage moderately severe acute postoperative pain — potentially the first NSAID approved for continuous infusion in the U.S., with patent protection through 2032; and NTM-006, a non-opioid, non-NSAID, non-gabapentinoid new chemical entity licensed from Johnson & Johnson in 2019, in development as a once-daily oral treatment for chronic neuropathic and nociplastic pain. Supporting pipeline candidates include NTM-002 (an IV patient-controlled analgesia candidate) and additional early-stage non-opioid programs.

Neumentum's business model is pre-commercial and primarily licensing-oriented. It generates limited revenue through upfront payments, milestone payments, and royalties from licensing partnerships — most notably the October 2020 agreement with Nuance Biotech granting exclusive China development and commercialization rights for NTM-001 ($3M upfront, up to $50M in milestones, plus low-double-digit royalties). The planned U.S. go-to-market is enterprise field sales targeting hospital procurement, pharmacy & therapeutics committees, and anesthesia/pain specialists for formulary adoption. The company has been funded through multiple equity rounds totaling approximately $34–36M, including a 2017 Series A and a 2023 exempt securities offering of up to $20M to support Phase 3 execution.

Neumentum firmographics

Firmographics
Name
Neumentum
Legal name
Neumentum, Inc.
Website
https://neumentum.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Neumentum is a clinical-stage pharmaceutical company developing a portfolio of novel non-opioid analgesic products, including an IV ketorolac formulation (NTM-001) and an oral analgesic NCE (NTM-006), targeting hospital-based acute and chronic pain markets to address the opioid crisis.
Ownership category
akta.pro rank

Neumentum industry classification

Industry
Product category
Non-opioid analgesics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Non-opioid analgesics
  • Pain management pharmaceuticals
  • Acute postoperative pain
  • Chronic neuropathic pain
  • Neurology specialty drugs

Where Neumentum is headquartered

Location

Headquarters

HQ city
Morristown
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Neumentum business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing Revenue: Licensing agreements for NTM-001 and NTM-006 generate upfront payments, milestone payments tied to development and regulatory achievements, and royalty payments on net sales.
  2. Equity Financing: Exempt securities offerings to raise capital for development operations. $20 million offering with $16.56 million already sold per SEC Form D.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Neumentum product offering

Product offering

Core offering

Neumentum develops and commercializes novel non-opioid pain pharmaceutical products. Its lead candidate NTM-001 is an alcohol-free, pre-mixed bag formulation of ketorolac designed for 24-hour continuous IV infusion for moderately severe postoperative acute pain. NTM-006 is a non-opioid, non-NSAID, non-gabapentinoid oral new chemical entity for chronic neuropathic and nociplastic pain. The company has four non-opioid candidates in development targeting hospitals and chronic pain patients.

Product overview

Neumentum is a specialty pharmaceutical company developing a portfolio of non-opioid analgesic products for pain management. The company's core pipeline includes NTM-001 (an IV alcohol-free ketorolac formulation in pre-mixed bag for 24-hour continuous infusion targeting acute postoperative pain), NTM-006 (an oral non-opioid, non-NSAID new chemical entity for chronic neuropathic and nociplastic pain), NTM-002 (IV patient-controlled analgesia candidate), and early-stage pipeline candidates. The company aims to address the opioid crisis by providing effective pain relief without the risks of abuse, misuse, diversion, or life-threatening respiratory depression associated with opioids.

Differentiator

Problem solved

Functional benefit

Products and services

  • NTM-001 (ketorolac pre-mixed bag for continuous infusion) Investigational, alcohol-free, stable formulation of ketorolac (an NSAID) in a pre-mixed bag designed for 24-hour continuous IV infusion in postoperative settings. Developed for management of moderately severe acute pain requiring analgesia at the opioid level, with the goal of reducing or eliminating opioid use after surgery. Target customers are hospitals, surgical centers, and anesthesia/pain management specialists.
  • NTM-006 (oral analgesic, formerly JNJ-10450232) Once-daily oral new chemical entity (NCE) that is non-opioid, non-NSAID, and non-gabapentinoid, with a novel mechanism of action. In development for chronic neuropathic and nociplastic pain, addressing patients with limited safe long-term oral options. Licensed-in from Johnson & Johnson Family of Companies.
  • NTM-002 (IV patient-controlled analgesia candidate) Early-stage IV patient-controlled analgesia candidate with potential to deliver opioid-strength analgesia, intended to reduce the need for opioids in clinical acute pain settings.
  • Early Stage Pipeline Early-stage non-opioid pharmaceutical pipeline candidates for the treatment of acute and chronic pain, both in the United States and globally, completing a portfolio of four novel non-opioid products.

Quantifiable outcome

  • Steady plasma levels of ketorolac over 24 hours demonstrated in Phase I study with 67 subjects
  • +1 more outcomes

Companies that use Neumentum

Customer profile

Segments2 records

Ideal customer profiles2 records

Neumentum technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Neumentum partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered secondary and core.

  • NEMA Research Inc.secondaryStrategic or Co-development Partner · 20 September 2021Clinical research organization partnership, jointly nominated for Citeline Awards 2021 for Most Successful Early-Phase Research. NEMA Research provides clinical trial services for Neumentum's pain management product development.
  • Nuance Biotech Co. LtdcoreOEM/ Whitelabel/ Licensing Partner · 21 October 2020Licensing agreement granting Nuance exclusive rights to develop and commercialize NTM-001 (ketorolac for IV infusion) in China. Neumentum receives $3 million upfront payment with potential development, regulatory and sales milestone payments up to $50 million plus low-double-digit percentage royalties on net sales. Nuance is a China-based specialty pharmaceutical company focused on pain management, founded in 2014.
  • Janssen Pharmaceutica NVcoreOEM/ Whitelabel/ Licensing Partner · 10 October 2019Global licensing agreement for JNJ-10450232 (now NTM-006) and portfolio of backup compounds. JNJ-10450232 is a novel oral analgesic compound that is neither an opioid nor NSAID, with Phase 2A clinical studies completed. Licensed from Johnson & Johnson Family of Companies.
  • McNeil Consumer Pharmaceuticals Co.coreOEM/ Whitelabel/ Licensing Partner · 10 October 2019Part of Johnson & Johnson Family of Companies, co-licensor of NTM-006 oral analgesic compound.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Neumentum competitors and assessment

Company assessment

Direct peers

  • Heron Therapeutics: Specialty pharmaceutical company developing non-opioid and oncology-supportive care products, including post-operative pain therapies (HTX-011/Zynrelef). Directly comparable as a non-opioid pain-focused specialty pharma with hospital channel commercialization.
  • Pacira BioSciences: Commercial-stage specialty pharma focused on non-opioid pain management with Exparel (bupivacaine liposome injectable suspension). The most established non-opioid post-surgical pain company, comparable for both product category and hospital formulary GTM motion.
  • Trevena: Specialty pharma focused on non-opioid pain therapeutics, with FDA-approved OLINVYK (oliceridine), an IV opioid agonist for moderate-to-severe acute pain. Comparable as a small-cap non-opioid pain developer with similar hospital-channel commercialization.
  • Cara Therapeutics: Clinical-stage biopharma developing novel peripherally-acting kappa opioid receptor agonists for chronic pruritus and pain. Comparable as a small specialty pharma targeting non-opioid pain pathways with similar development-stage profile.
  • AcelRx Pharmaceuticals: Specialty pharma commercializing DSUVIA (sufentanil sublingual) and ZALVISO for acute pain in medically supervised settings. Comparable focus on opioid-sparing or alternative pain therapies with hospital/clinical channel strategy.
  • Centrexion Therapeutics: Clinical-stage biopharma developing non-opioid treatments for chronic pain (e.g., CNTX-6016, capsaicin-based therapies). Directly comparable as a pure-play non-opioid pain therapeutics developer targeting similar patient populations.

Emerging players

  • Baudax Bio: Specialty pharma with ANJESO (meloxicam IV) for moderate-to-severe pain and a non-opioid portfolio. Comparable as a small-cap non-opioid pain developer with hospital-channel commercialization focus.
  • Concentric Analgesics: Clinical-stage biopharma developing CA-008, a non-opioid prodrug of capsaicin for post-surgical pain. Directly comparable as an emerging non-opioid acute pain developer with similar Phase-stage profile.

Broad incumbents

  • Pfizer: Global pharmaceutical incumbent with established ketorolac generic franchise (Toradol) and broad pain portfolio. Comparable as a competitor and potential strategic acquirer/partner for non-opioid pain assets with deep hospital relationships.
  • Grünenthal GmbH: Privately-held European specialty pharma with deep focus on pain management (including Qutenza, tapentadol/Palexia). Highly comparable as a chronic and acute pain specialist incumbent and potential strategic acquirer given Neumentum's CMO Ilona Steigerwald previously led late R&D there.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Neumentum social profiles

Digital presence

Neumentum financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neumentum leadership team

Management profile

Number of profiles

Profiles4 records

Neumentum funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neumentum M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neumentum

What does Neumentum do?

Neumentum develops and commercializes novel non-opioid pain pharmaceutical products. Its lead candidate NTM-001 is an alcohol-free, pre-mixed bag formulation of ketorolac designed for 24-hour continuous IV infusion for moderately severe postoperative acute pain. NTM-006 is a non-opioid, non-NSAID, non-gabapentinoid oral new chemical entity for chronic neuropathic and nociplastic pain. The company has four non-opioid candidates in development targeting hospitals and chronic pain patients.

Is Neumentum a public or private company?

Neumentum is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neumentum founded?

Neumentum was founded in 2017. It employs 1 to 10 people.

Where is Neumentum based?

Neumentum is headquartered in Morristown, United States, in the North America region.

How does Neumentum make money?

Two revenue lines are on record. Licensing Revenue is the primary driver. The others are equity Financing.

Who are Neumentum's main competitors?

Direct peers on record are Heron Therapeutics, Pacira BioSciences, Trevena, Cara Therapeutics, AcelRx Pharmaceuticals and Centrexion Therapeutics. Emerging players are Baudax Bio and Concentric Analgesics. Broad incumbents are Pfizer and Grünenthal GmbH.

Does Neumentum have an API?

No public API is recorded for Neumentum.

What industry is Neumentum in?

Neumentum's product category is Non-opioid analgesics. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BarchartAcute Pain Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Vertex Pharma, Heron Therapeutics, Neumentum, Cali BiosciencesDelveInsight released a market forecast report projecting the global acute pain market to grow from USD 4.5 billion in 2025 to USD 15.5 billion by 2036, driven by rising surgical volumes and demand for non-opioid treatments. The analysis highlights key industry players including Vertex Pharmaceuticals, Heron Therapeutics, Neumentum, Cali Biosciences, and PainReform, while also noting recent corporate developments such as Merck's acquisition of Cidara Therapeutics.SecSEC FORM DNeumentum, Inc. filed a Form D with the SEC to announce an exempt securities offering under Rule 506(b) with a total offering amount of $20 million. The filing indicates that approximately $16.6 million has been sold to 33 investors so far, with Brookline Capital Markets acting as the broker-dealer for the transaction.NewswireNeumentum Announces Initiation of Phase 3 Program Evaluating Its Lead Product Candidate, NTM-001, for the Management of Moderately Severe Acute PainNeumentum has initiated a Phase 3 clinical program to evaluate its lead product candidate, NTM-001, for the management of moderately severe acute pain. The study compares NTM-001 against placebo and includes a morphine arm to assess assay sensitivity in patients undergoing bunionectomy surgery. Results from this efficacy and safety trial are expected in the second half of 2023.Scranton Times-TribuneNEPA native honored for achievements in accounting, financeTaggart McGurrin was promoted to chief business officer and corporate secretary at Neumentum, a pharmaceutical startup, and received the Rising Star Award from Informa Connect for his contributions to the company. McGurrin has played a vital role in Neumentum's growth since 2017, particularly in building investor relationships to support its mission of developing nonopioid pain alternatives. The company is currently preparing for a Phase 3 clinical trial for its lead candidate NTM-001 and holds licensing rights for NTM-006 from Johnson & Johnson.SecSEC FORM DNeumentum, Inc. filed a Form D with the SEC for an exempt securities offering under Rule 506(b), disclosing a total offering amount of $20 million. The filing indicates that $13.3 million has been sold to 28 investors as of September 30, 2021, with $6.7 million remaining.GlobeNewswireNeumentum and NEMA Research Inc. Named to Short-List of Citeline Awards for 2021Neumentum and NEMA Research were nominated for the Citeline Award for Most Successful Early-Phase Research Company. The study tested a 48-hour continuous infusion of ketorolac tromethamine, demonstrating safety and toxicology. The award ceremony is set for October 14, 2021, in Boston.PR NewswireNeumentum Phase I Study Confirms Its Non-Opioid in Development for Moderately Severe Acute Pain, NTM-001, Performs in Healthy Adults as PredictedNeumentum announced findings from its Phase I study of NTM-001, a novel alcohol-free formulation of ketorolac in a pre-mixed bag for continuous 24-hour IV infusion, confirming the non-opioid pain treatment performed as predicted in healthy adult volunteers with no unexpected adverse effects. The study of 67 subjects across four cohorts at two sites demonstrated consistent, steady blood plasma levels of ketorolac over 24 hours, validating the pharmacokinetic modeling previously shared with the FDA. Neumentum plans to meet with the FDA on January 29 and subsequently initiate its Phase III program.PR NewswireNeumentum Announces Dosing of Patients in Phase I Study Evaluating Its Lead Product Candidate, NTM-001, a Non-Opioid in Development for the Management of Moderately Severe Acute PainNeumentum announced the completion of dosing the first cohort of patients in its Phase I clinical study for NTM-001, an investigational non-opioid pain management candidate. The company plans to initiate a pivotal Phase III study in early 2019 following successful completion of this Phase I trial and an end-of-phase II meeting with the U.S. Food and Drug Administration.PR NewswireProfNet Experts Available on Opioid Crisis, Alternative Drug Abuse, MorePR Newswire's ProfNet network released a list of available experts for media inquiries, covering topics such as the opioid crisis, alternative drug abuse, and emotional wellness. The announcement highlights specific individuals like Scott Shively of Neumentum and Dr. Christopher Metzler of Gordium Healthcare to assist journalists in reporting on these health issues.FinSMEsNeumentum Raises $6M in Series A FundingNeumentum raised $6M in Series A funding, with Brookline Capital Markets as placement agent. The company will use the funds to advance non-opioid pain drug candidates, including NTM-001 and NTM-002. It also requested a Type B meeting with the FDA for NTM-001's Phase 3 program.